Compare FOR & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | VIR |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2007 | 2019 |
| Metric | FOR | VIR |
|---|---|---|
| Price | $27.79 | $9.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $32.67 | $19.43 |
| AVG Volume (30 Days) | 121.2K | ★ 1.4M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $1,662,400,000.00 | $68,556,000.00 |
| Revenue This Year | $0.34 | $270.22 |
| Revenue Next Year | $7.73 | N/A |
| P/E Ratio | $29.49 | ★ N/A |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $18.73 | $4.16 |
| 52 Week High | $30.74 | $11.66 |
| Indicator | FOR | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 51.45 |
| Support Level | $24.22 | $8.48 |
| Resistance Level | $29.05 | $10.29 |
| Average True Range (ATR) | 0.84 | 0.42 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 85.00 | 69.78 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.